Skip to main content
Equibles
ANRO logo

ANRO · Alto Neuroscience, Inc. · Metrics

Track ANRO — free

Use ANRO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANRO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$21.97 -0.23 (-1.04%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$862.15M
Shares
39.24M
Volume · Oct 23 379.26K Avg daily vol (3M) 554.74K

ANRO metrics

63 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$21.97
Market cap
$862.15M

Price action

20 metrics
Price change (1W)
+0.1%
Price change (30D)
-17.1%
Price change (3M)
-18.0%
Price change (6M)
-10.4%
Price change (YTD)
+23.4%
Price change (1Y)
+96.5%
Trailing year
Price change (5Y)
—
52-week high
$36.64
52-week low
$11.00
Change from 52-week high
-40.0%
Change from 52-week low
+99.7%
Annualized volatility
78.8%
Annualized volatility (3M)
57.1%
Beta
1.8
RSI (14D)
34.4
Price vs SMA 50
-25.2%
Price vs SMA 200
-8.8%
Avg volume (3M)
554,735
Relative volume
0.7
Average dollar volume
$15.83M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
39.24M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.9
reciprocal yield 25.4%
FCF yield
-8.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-9.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-16

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$88.27M
Net income (TTM)
−$84.24M
Trailing 12 months
Diluted EPS (TTM)
$-2.43
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$4.73

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+58.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-38.4%
Return on assets
-33.2%
Debt / equity
0.1
Current ratio
14.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$68.84M
Quick ratio
14.9
Interest coverage
-39.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$227.55M
Latest balance sheet
Cash & equivalents
$243.73M
Total assets
$254.07M
Total debt
$16.19M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$68.28M
Capital expenditures (TTM)
$556,000
R&D (TTM)
$64.92M
SG&A (TTM)
—
Stock compensation (TTM)
$10.51M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
116
13F filer change QoQ
+5
Institutional ownership
75.4%
Conviction holders (share of 13F filers)
3.5%
Crowding (high-turnover and private-fund holders)
58.1%
Private-fund adviser ownership
57.7%
Active holders' share change QoQ
-1.7%
Holder tenure
5.9
Price vs estimated holder cost
+69.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.5%

Short interest

3 metrics
Short interest
11.9%
Latest settlement · 6.5 days to cover
Days to cover
6.5d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.57M
Insider-sentiment score
23 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1999480 CUSIP 02157Q109 13F (30d) 10 filings 10 filers Visit website Investor relations